Woburn, MA – According to filings with the U.S. Securities and Exchange Commission, Frequency Therapeutics is raising $42,301,944.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Lucchino played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Frequency Therapeutics

We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s lead product candidate, FX-322, is a potential disease modifying therapy designed to regenerate auditory hair cells to improve hearing function.

To learn more about Frequency Therapeutics, visit http://www.frequencytx.com/

Contact:
David Lucchino, Chief Executive Officer
781-315-4600
https://www.linkedin.com/in/david-l-lucchino-0490421/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved